Pharmatest Services participates in Tumor Models event In Boston

Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services Ltd (Pharmatest) will attend the Hanson Wade Tumor Models Summit in Boston, Massachusetts later this month.

Pharmatest will deliver a sponsored talk and three poster presentations during the event and will also be a Spotlight Partner to the event, as well as an exhibitor. The Pharmatest Booth at Le Meriden Hotel will showcase the organization’s range of preclinical efficacy services for the pharmaceutical industry, including a wide range of in vitro and in vivo models in the fields of oncology and skeletal diseases.

Predictive models

Pharmatest has developed special expertise in clinically predictive orthotopic and metastasis models, particularly models of bone metastasis, which will form the subjects of several scientific presentations at the Summit. These include:

• Sponsored talk by Dr. Sanna Käkönen (consultant for Pharmatest from Aurexel) on Thursday, July 23 at 10.20 am: “Breaking the morbid bond – Identifying compounds to silence the vicious crosstalk between tumor and bone microenvironment utilizing bone metastasis models.”
• Poster presentation by Dr. Johanna Tuomela: “Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis.”
• Poster presentation by Dr. Jenni Bernoulli: “Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models.”
• Poster presentation by Dr. Jenni Bernoulli: “Novel luciferase labeling technique to improve imaging of orthotopic pancreatic cancer model.”

Pharmatest is accepting advance notifications to schedule meetings with its team at the Tumor Models Summit. Those interested should contact the organization at: [email protected]

About Pharmatest

Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

The CRO has supported close to 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

About Tumor Models 2015

The 3rd annual Tumor Models Summit is a three-day event opening July 21 at Le Méridien Cambridge-MIT Hotel in central Boston, Massachusetts.

The Tumor Models Series, organized by Hanson Wade, provides a platform for the preclinical oncology community to explore next generation models for preclinical strategies.

The 2015 Summit Boston will once again focus on clinically relevant tumor models enhancing translatability for more predictable late stage clinical trials, as well as innovative in vitro and in vivo models. It will feature more than 25 speakers and is expected to attract more than 80 oncology scientists and researchers.

More information available at: http://tumor-models.com